Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate on drug imports

This article was originally published in The Tan Sheet

Executive Summary

The full Senate has voted to allow prescription drug importation through the passage of an amendment to the Homeland Security Appropriations bill. The amendment, proposed by Sens. David Vitter (R-La.) and Bill Nelson (D-Fla.), prevents funds from being used by the U.S. Customs & Border Protection to prevent individuals from importing prescription drugs from Canada for personal use. The measure passed 68 to 32 on July 11. The original version of the amendment did not include any restrictions on country of origin. However, during floor debate, Vitter added the limitation that only drugs imported from Canada be allowed. An importation provision could survive the eventual conference committee; the House appropriations bill also included a section that would allow for importation. A Senate Health Committee spokesperson said he expects Chairman Michael Enzi (R-Wyo.) to oppose an importation provision in conference. The Senate is expected to pass the Homeland Security bill this week...

You may also be interested in...



Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.

Topics

UsernamePublicRestriction

Register

PS099571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel